CPI-200 is under clinical development by Coordination Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CPI-200’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CPI-200 is under development for the treatment of solid tumor. It is administered as intravenous infusion. It is developed based on nanoscale coordination polymer (NCP) platform technology.
Coordination Pharmaceuticals overview
Coordination Pharmaceuticals, Inc., an immune-oncology company commercializing the nanoscale coordination polymer (NCP) technology for immunotherapy of recurrent and metastatic solid tumors. The company is headquartered in United States.
For a complete picture of CPI-200’s drug-specific PTSR and LoA scores, buy the report here.